Immuneering Announces Participation in December Investor Conferences

Rhea-AI Summary

Immuneering Corporation (Nasdaq: IMRX) announced its participation in several December investor conferences to discuss its oncology pipeline and business strategy. Key events include the Piper Sandler Global Healthcare Conference and Evercore ISI HealthCONx Conference, where executives will engage in investor meetings and fireside chats. The company focuses on developing therapies that target oncogenic signaling pathways, notably with its lead product candidate IMM-1-104, aimed at advanced solid tumors. Immuneering emphasizes its proprietary platform driven by translational bioinformatics.

Positive

• Participation in multiple investor conferences enhances investor communication.
• Focus on proprietary oncology pipeline with drugs targeting specific signaling pathways.
• Lead candidate IMM-1-104 designed for precision targeting of RAS mutant tumors.

Negative

• None.

Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cells

CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will participate in several December investor conferences to share commentary with investors around the Company’s pipeline, platform and business strategy.

Immuneering will present virtually at the following conferences:

Piper Sandler 33rd Annual Global Healthcare Conference (November 30 – December 2, 2021)

• Format: Fireside Chat and 1x1 Investor Meetings
• Fireside Chat Available On-Demand: Beginning November 22, 2021 at 10:00 am ET

4th Annual Evercore ISI HealthCONx Conference (November 30 – December 2, 2021)

• Format: Fireside Chat and 1x1 Investor Meetings
• Fireside Chat: December 1, 2021 from 2:15-2:35 pm ET

Oppenheimer AI Summit (December 7, 2021)

• Format: Company Presentation
  

The presentations from the Piper Sandler 33rd Annual Global Healthcare Conference and 4th Annual Evercore ISI HealthCONx Conference will be webcast live and available for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation                                        
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.        

Forward-Looking Statements

This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the offering filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.        

Corporate Contact:
Rebecca Kusko, Ph.D.
Immuneering Corporation
617-500-8080
rkusko@immuneering.com

Investor Contact:
Susan Noonan
Rx Communications
susan@sanoonan.com

FAQ

What investor conferences will Immuneering participate in December 2021?

Immuneering will participate in the Piper Sandler 33rd Annual Global Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference from November 30 to December 2, 2021.

What is Immuneering's lead product candidate?

Immuneering's lead product candidate is IMM-1-104, a dual-MEK inhibitor targeting advanced solid tumors in patients with RAS mutations.

What is the focus of Immuneering's pipeline?

Immuneering's pipeline focuses on oncology and neuroscience product candidates that disrupt cellular signaling dynamics to improve patient outcomes.

Where can I find recordings of Immuneering's conference presentations?

Recordings of Immuneering's conference presentations will be available on their Investor Relations website for 30 days following the events.